Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSR-042 (dostarlimab) + niraparib vs niraparib vs chemotherapy in metastatic or recurrent endometrial or ovarian carcinosarcoma
2019-002662-12Phase 2Active
- Sponsor
- Arcagy-Gineco
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dostarlimab and niraparib in endometrial carcinosarcoma, ovarian carcinosarcoma (OCS) and ovarian cancer (3 arms), sponsored by Arcagy-Gineco. Primary endpoint: Phase II selection endpoint. Started Nov 2019; status: active.
02
Drugs
dostarlimabniraparib
03
Conditions
endometrial carcinosarcomaovarian carcinosarcoma (OCS)ovarian cancer
Beyond the preview
Go deeper on 2019-002662-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002662-12.